CoChat
Sign Up
Cited by 119Bone health and osteoporosis researchLiver Diseases and ImmunityBone health and treatments

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Alendronate Is More Effective Than Etidronate for Increasing Bone Mass in Osteopenic Patients With Primary Biliary Cirrhosis

Guañabens, Nuria, Parés, Albert, Ros, Inmaculada, Alvarez, Luisa, Pons, Francesca, Caballería, Llorenç, Monegal, Ana, de Osaba, Jesus Martínez M., Roca, Merce, Peris, Pilar, Rodés, Juan·2003·American Journal of Gastroenterology
DOI 10.1111/j.1572-0241.2003.07639.x
Open this paper in CoChat — free account

Abstract

OBJECTIVES: Osteopenia increases the morbidity of primary biliary cirrhosis (PBC). In this study, we have compared two bisphosphonates, alendronate and cyclical etidronate, that inhibit osteoclast-mediated bone resorption and have examined their effects on bone mass in patients with this disease. METHODS: A total of 32 women with PBC were randomly assigned to receive alendronate (10 mg/day) or etidronate (400 mg/day) for 14 days every 3 months. Bone mineral density of the lumbar spine and proximal femur were measured initially and every 6 months. Bone fractures and markers of bone mineral metabolism were also evaluated. RESULTS: Sixteen patients were allocated to each group, which were comparable with respect to the severity of PBC and osteopenia. Thirteen patients in each group completed the 2-yr trial. Both treatments increased bone mineral density after 2 yr, although the increase at the lumbar spine and at the proximal femur was significantly higher in patients receiving alendronate than in patients on etidronate. This higher effect of alendronate paralleled with changes in the biochemical markers of bone turnover. No patient developed new vertebral fractures, but new peripheral fractures were detected in two patients on alendronate and in one on etidronate. There were no serious adverse effects. Neither treatment impaired liver function or cholestasis. CONCLUSIONS: Alendronate effectively increases bone mass and has greater antiresorptive power than etidronate in patients with primary biliary cirrhosis, and is associated with minor or no side effects.

Overview

Integrity signals

Registry

Crossref · 10.1111/j.1572-0241.2003.07639.x

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 26

  1. Diamond T.H., 1990, J Gastroenterol Hepatol, 5, 66, 10.1111/j.1440-1746.1990.tb01768.x · DOI
  2. Guanabens N., 1990, Am J Gastroenterol, 85, 1356
  3. 10.1016/0270-9139(91)91418-Z · DOI
  4. Lindor K.D., 1993, Semin Liv Dis, 13, 367, 10.1055/s-2007-1007365 · DOI
  5. Matloff D.S., 1982, Gastroenterology, 83, 97, 10.1016/S0016-5085(82)80291-6 · DOI
  6. Herlong H.F., 1982, Gastroenterology, 83, 103, 10.1016/S0016-5085(82)80292-8 · DOI
  7. Floreani A., 1991, J Hepatol, 12, 217, 10.1016/0168-8278(91)90941-4 · DOI
  8. Camisasca M., 1994, Hepatology, 20, 633, 10.1016/0270-9139(94)90098-1 · DOI
  9. Crippin J.S., 1994, Am J Gastroenterol, 89, 47
  10. Olsson R., 1999, Liver, 19, 188, 10.1111/j.1478-3231.1999.tb00034.x · DOI
  11. 10.1016/0168-8278(92)90066-X · DOI · Paper page
  12. Storm T., 1990, N Engl J Med, 322, 1265, 10.1056/NEJM199005033221803 · DOI
  13. Watts N.B., 1990, N Engl J Med, 323, 73, 10.1056/NEJM199007123230201 · DOI
  14. Guanabens N., 1997, Gastroenterology, 113, 219, 10.1016/S0016-5085(97)70098-2 · DOI
  15. 10.1056/NEJM199511303332201 · DOI
  16. 10.1210/jc.85.9.3109 · DOI
  17. 10.1056/NEJM199610033351403 · DOI
  18. 10.1056/NEJM200008313430902 · DOI
  19. 10.1016/S0140-6736(96)07088-2 · DOI · Paper page
  20. 10.1007/s001980050048 · DOI
  21. 10.1001/jama.277.14.1159 · DOI
  22. Maconi G., 1995, Am J Gastroenterol, 90, 1889
  23. 10.1001/archinte.160.4.517 · DOI
  24. 10.1111/j.1572-0241.2000.01835.x · DOI
  25. 10.1016/S0002-9270(98)00099-9 · DOI
  26. 10.1056/NEJM200008033430512 · DOI

Cited by

Sorted by citations

Metadata

Authors
Guañabens, N., Parés, A., Ros, I., Alvarez, L., Pons, F., Caballería, L., Monegal, A., de Osaba, J. M. M., Roca, M., Peris, P., & Rodés, J.
Affiliations
  • Hospital Clínic de Barcelona (ES)
  • Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
ORCID
Venue
American Journal of Gastroenterology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2003-10
Volume
98
Issue
10
Pages
2268-2274
ISSN
0002-9270 (ISSN-L)
DOI
10.1111/j.1572-0241.2003.07639.x
OpenAlex
W2111992737
Cited by
119
References
3
Citations by year
2026: 1 · 2025: 2 · 2024: 1 · 2023: 3 · 2022: 1 · 2021: 2 · 2020: 1 · 2019: 4 · 2018: 8 · 2017: 4 · 2016: 5 · 2015: 4 · 2014: 4 · 2013: 4 · 2012: 10
FWCI
7.72
Type
journal article
Language
en
Open access
closed
Locations
  • The American Journal of Gastroenterology (publishedVersion)
  • PubMed (publishedVersion)
Funders
Instituto de Salud Carlos III
Topics
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
  • Health Sciences › Medicine › Oncology › Bone health and treatments
Keywords
alendronate, etidronate, primary biliary cirrhosis, osteopenia, bone mineral density, bisphosphonates, bone resorption, bone turnover markers, vertebral fractures, peripheral fractures, antiresorptive therapy
MeSH terms
Adult, Aged, Densitometry, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Liver Cirrhosis, Biliary, Middle Aged, Probability, Reference Values, Severity of Illness Index, Etidronic Acid, Bone Density, Osteoporosis, Postmenopausal, Bone Remodeling, Treatment Outcome, Alendronate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review